inflammatory diseases

Affibody gets izokibep ‘back on track’ after Acelyrin rejection

Affibody may not have expected to be working on izokibep again, but the Swedish biotech hasn’t wasted an opportunity to showcase the drug’s potential.

James Waldron Jun 5, 2026 10:42am

Three blocks displaying from left to right a person a handshake and another person

Boehringer makes €407M bet on Immunitas’ inflammatory asset

May 12, 2026 9:57am

White arrow on a road pointing to the rising sun

Avalo’s phase 2 win fuels AbbVie chase despite placebo headwind

May 6, 2026 6:00am

Windward breezes toward phase 3 with $165M for TSLP ambitions

May 4, 2026 10:31am

Lipella goes bankrupt, ending mouth inflammation drug ambitions

Mar 31, 2026 7:20am

Living cells illustration Cells membrane with nucleus are floating Medical and science concept background 3D render

After $1B fundraise, Xaira breaks silence on AI work

Mar 17, 2026 2:52pm